SCHEMBL7928883

SCHEMBL7928883

CC(=O)c1cc(NC(=O)c2c(F)cccc2F)ccc1-c1cc(-c2cccnc2)sc1CO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.47
▸ MAPT P10636 1/20 0.44
▸ DYRK1A Q13627 2/20 0.42
▸ DYRK1B Q9Y463 1/20 0.42
▸ BRAF P15056 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NOD2 Q9HC29 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ CYP11B1 P15538 2/20 0.39
▸ CYP11B2 P19099 2/20 0.39
▸ CSF1R P07333 2/20 0.39
▸ DYRK3 O43781 1/20 0.39
▸ PRKD3 O94806 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13321606 0.92 LMNA (0.45) LMNAMAPTDYRK1ADYRK1BBRAF
SCHEMBL13640661 0.86 LMNA (0.47) LMNAMAPTDYRK1ADYRK1BBRAF
SCHEMBL2894859 0.79 LMNA (0.55) LMNAMAPTDYRK1ADYRK1BJAK2
SCHEMBL13321607 0.78 LMNA (0.45) LMNAMAPTDYRK1ADYRK1BBRAF
SCHEMBL2315507 0.78 LMNA (0.56) LMNAMAPTDYRK1ADYRK1BJAK2
SCHEMBL2315252 0.78 LMNA (0.51) LMNAMAPTDYRK1ADYRK1BJAK2
SCHEMBL2315494 0.77 LMNA (0.52) LMNAMAPTDYRK1ADYRK1BJAK2
SCHEMBL7917075 0.77 LMNA (0.52) LMNAMAPTDYRK1ADYRK1BJAK2
SCHEMBL2886943 0.73 LMNA (0.55) LMNAMAPTDYRK1ADYRK1BBRAF
SCHEMBL4768204 0.71 IL2 (0.60) LMNADYRK1ADYRK1BBRAFJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165451-A9 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2013-06-27 — — US disclosed
US-20120283272-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2012-11-08 — — US disclosed
WO-2010039237-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2010-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283272-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CXCL8, CCR1, CCR8 LMNA 4757/4885MAPT 1028/4885DYRK1A 4239/4885
US-20130165451-A9 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CXCL8, CCR1, CCR8 LMNA 4757/4885MAPT 1028/4885DYRK1A 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback